MOTS-c Peptide: Research Record, Legal Status, and Where to Buy (2026)

From mitochondrial DNA to the folate cycle and AMPK

MOTS-c is unusual because its coding origin is mitochondrial rather than nuclear. The 2015 discovery study describes a 16-residue peptide encoded by a 51-base-pair short open reading frame within the mitochondrial 12S rRNA region. In HEK293 cells and mice, the researchers found inhibition of the folate cycle and linked de novo purine biosynthesis, an increase in AICAR, and activation of AMPK. Their mouse insulin-sensitivity experiments identified skeletal muscle as the principal target tissue.

The sequence hangs together: folate-cycle inhibition changes purine synthesis, AICAR rises, AMPK switches on. All of it is cell and mouse work. No completed human study has followed that chain in people, because no verifiable registered study has administered the peptide.

A 2021 study of exercise and aging added changes in nuclear genes related to metabolism and proteostasis, skeletal-muscle metabolism, and myoblast stress adaptation. It also observed exercise-associated increases in endogenous MOTS-c in human skeletal muscle and circulation. Those human observations followed the body's own peptide levels during exercise; participants were not given MOTS-c.

For a receptor-based comparison with other metabolic compounds in the catalogue, retatrutide vs. tirzepatide vs. semaglutide maps how their targets differ from one another.

What the mouse protocols actually administered

The metabolic findings most often associated with MOTS-c come from named mouse experiments with defined schedules. In the 2015 mouse study, researchers administered 5 mg/kg/day split into two daily administrations for four days in an acute normal-diet experiment. They also administered 5 mg/kg/day intraperitoneally for seven days in insulin-sensitivity experiments, and 0.5 mg/kg/day intraperitoneally for three or eight weeks in high-fat-diet experiments. The study reported improved glucose handling and prevention of high-fat-diet-induced obesity and insulin resistance in mice.

The 2021 physical-performance study administered 5 or 15 mg/kg/day intraperitoneally in young, middle-aged, and old mice. A late-life intermittent experiment used 15 mg/kg/day three times weekly. The reported physical-performance effects belong to those mouse protocols, while the human component measured endogenous MOTS-c around exercise.

These amounts describe experimental administration to mice. They do not supply a human protocol, and the 10 mg catalogue size is a product variant, not a protocol amount. Researchers working with catalogue material can separately consult Curo's guide to storing research peptides and bacteriostatic water.

K14Q links a human cohort signal to mouse experiments

The mitochondrial DNA variant m.1382A>C, rs111033358, produces a Lys14Gln substitution, abbreviated K14Q. In the 2021 K14Q study, a meta-analysis across the J-MICC, MEC, and TMM cohorts included 27,527 participants. The C allele was associated with higher type 2 diabetes prevalence in men, but not in women.

The same paper extended the variant work into mice. One experiment administered wild-type or K14Q peptide at 7.5 mg/kg intraperitoneally twice daily for 21 days; another used 0.5 mg/kg intraperitoneally daily for 21 days. In mice carrying the variant, the calculated clearance rate for K14Q was 2.6-fold slower than for wild-type MOTS-c after intraperitoneal osmotic-pump administration.

The cohort finding is a genetic association in people, not a result from giving anyone the peptide. The clearance figure is relative and comes from mice, so it is not a human half-life. One detail is worth getting right, because it circulates wrongly: the substitution is K14Q, not K14R. What the K14Q work does is make a single residue matter to MOTS-c biology in humans and mice at once. What it does not do is tell you what an administered dose does. Human clearance, bioavailability, distribution, metabolism and excretion are all still open.

A 7-5 recommendation, with no human administration data

The Federal Register notice published April 16, 2026 put MOTs-C free base and MOTs-C acetate in front of FDA's Pharmacy Compounding Advisory Committee on July 23, 2026, under docket FDA-2025-N-6895, naming obesity and osteoporosis as the evaluated uses.

The committee recommended both forms for the Section 503A bulks list, by the narrowest margin of the two-day meeting: 7 in favor to 5 against, with two abstentions on each form. Hyman, Phelps & McNamara described it as a 7-5-2 margin, and Pharmaceutical Executive and McDermott Will & Schulte published the same figures. FDA's staff had argued the other way, its briefing document citing no human safety or effectiveness information alongside unresolved characterization and immunogenicity questions.

Read that against the registry and the two records sit oddly together. The committee weighed a compounding question in July 2026 with no verifiable registered study that gives MOTS-c to people, and none that has reported results. The recommendation is also advisory: FDA is not bound by it, and listing happens through rulemaking. FDA's meeting page holds the briefing documents, the questions and the archived broadcast, but no minutes or vote table.

For contrast on what a finished registry record looks like, follow Ipamorelin: a secretagogue that finished its trials.

Is MOTS-c legal to buy?

In the United States, MOTS-c is legal to purchase as a research chemical for laboratory use. It is not a controlled substance and does not appear on any DEA schedule as of September 2026. What MOTS-c is not: an approved drug, a dietary supplement ingredient, or a compound cleared for human or veterinary use in any form. FDA's substance record for UNII A5CV6JFB78 identifies the molecule and states plainly that a UNII does not imply regulatory review or approval.

Three boundaries define the current legal picture:

1. Research sale is lawful; human-use marketing is not. FDA has repeatedly cited peptide sellers whose sites promote human use, and courts have treated that line seriously. The owner of one vendor, Paradigm Peptides, was sentenced to 70 months in federal prison in July 2026 for selling unapproved and adulterated drugs. The offense was not the stocking of peptides. It was selling them for human consumption while faking the paperwork.
2. The compounding question is open, not settled. The July 2026 advisory vote points toward possible pharmacy compounding for obesity and osteoporosis in the future. Until FDA completes rulemaking, no compounded or prescription form of MOTS-c exists lawfully in the US.
3. The human evidence base is not a legal argument. FDA staff recorded no human safety or effectiveness information for MOTS-c in the July 2026 briefing document. Legality as a research chemical says nothing about characterization or immunogenicity questions that remain open.

None of this changes how a supplier like Curo operates: MOTS-c is sold strictly for laboratory research, not for human or animal use. Curo's research use only policy covers what that means in practice.

Where to buy MOTS-c for laboratory research

Researchers looking for where to buy MOTS-c face a supplier market that changed sharply in 2025 and 2026. Peptide Sciences closed in March 2026, Amino Asylum went offline after a reported federal raid in June 2025, and Paradigm Peptides ended in a criminal sentencing. Several sites now trade on those dead brand names, so the first check is not price. It is whether the company behind the storefront actually exists. Our guide to the best peptide companies in 2026 covers the current field vendor by vendor.

Five checks separate a documented MOTS-c source from an anonymous one:

1. A lot-specific COA, published before purchase. The certificate should match the exact lot on the vial, not a generic product-page badge. The help center shows how to verify a certificate against your lot.
2. A named, independent laboratory. A COA is only as good as the lab that issued it. Court records in the Paradigm case showed the defendants admitted faking certificates outright, which is the failure mode this check exists to catch.
3. Identity and purity by more than one method. HPLC purity alone leaves an identity gap. Look for LC-MS identity confirmation against the expected 2174.6 g/mol, plus endotoxin results.
4. An identifiable company. A legal entity, a real contact route, and consistent policies. A brand name alone is not an identity, and the clone sites trading on dead vendors prove it.
5. Payment with recourse. Card payment carries buyer protection. Venmo, Zelle, and crypto-only checkouts remove it.

Curo stocks MOTS-C 10mg in the research peptide catalogue. Every lot is tested by an independent laboratory for identity (LC-MS), purity (HPLC), and endotoxin, the full testing standard is documented, and every certificate is publicly readable without an account. Orders are fulfilled from the United States, and payment options include card, crypto, Zelle, and Cash App.

How much does MOTS-c cost?

As of August 2026, research-grade MOTS-c in the 10mg vial size runs roughly $60 to $100 from US suppliers that publish lot-matched, independently issued COAs before purchase. Cheaper vials exist, some in the $35 to $45 band, but they cluster among suppliers whose certificates are self-issued, available only on request, or not tied to the lot on the vial, and an unverified lot is unusable as research material at any price. Curo's MOTS-C 10mg is $69, in the lower third of the documented tier. Compare the documentation attached to the current batch first, then the price. The pre-purchase checklist walks the full sequence.

Vial size is where MOTS-c price comparisons go wrong most often. The common research sizes are 10mg, 20mg and 40mg, so a headline figure means nothing until it is normalized per milligram. Curo's $69 for 10mg works out to $6.90 per mg.

What a MOTS-c certificate of analysis should show

MOTS-c is synthesized by many suppliers, so material quality is something a lab confirms rather than assumes. Identity, purity, endotoxin load, and fill accuracy all vary by manufacturer and by lot. A certificate worth relying on shows:

• The exact lot number that appears on the vial.
• The issuing laboratory's name and report identifier.
• HPLC purity with the chromatogram, not a bare percentage.
• Mass-spectrometry identity confirmation against the expected 2174.6 g/mol for the 16-residue sequence MRWQEMGYIFYPRKLR.
• An endotoxin result, since a pure peptide can still carry bacterial contamination from synthesis.
• A way to verify the document independently, through a public lookup or the lab itself. Curo's COA database is open for exactly this reason.

A well-tested lyophilized peptide can still be degraded by poor handling after receipt. See storing research peptides and bacteriostatic water for the storage side.

For a broader framework on separating documentation from marketing when comparing suppliers, see how to evaluate research peptide companies and the companion piece on purity claims and COA batch documentation.

Further reading

Ipamorelin sits at the opposite end of the registry spectrum from MOTS-c: its studies were run, finished and reported decades ago, and the interesting question is why development stopped anyway. That record is set out in Ipamorelin: a secretagogue that finished its trials.

For a receptor-level comparison with the metabolic compounds MOTS-c is most often shelved next to, retatrutide vs. tirzepatide vs. semaglutide maps how their targets differ.

Frequently asked questions

How many MOTS-c clinical trials actually give participants MOTS-c?

None that can be verified. One record, NCT07505745 (MOTS-MET), is listed as an administration study, but its sponsor's filings fail basic integrity checks, including a sibling record that calls itself fictional. The other eight records measure MOTS-c as a biomarker or outcome.

Is the MOTS-MET trial real?

It cannot be verified. Its sponsor, Hudson Biotech, filed eight near-identical records in early 2026 that share one site and one contact, and one of them describes itself as fictional. Curo's registry count excludes all of that sponsor's records until the sponsor can be verified.

Is MOTS-c FDA approved?

No. FDA's substance record for UNII A5CV6JFB78 identifies MOTS-c and expressly says that a UNII does not imply regulatory review or approval.

Is MOTS-c legal to buy in the US?

Yes, as a research chemical for laboratory use. MOTS-c is not a controlled substance as of September 2026 and appears on no DEA schedule. It is not approved for human use, and no lawful compounded form exists, because the July 2026 advisory recommendation still has to go through FDA rulemaking before anything changes.

Where can a researcher buy MOTS-c?

From suppliers that publish lot-specific, independently issued COAs and operate as identifiable companies. Several well-known vendors closed or faced federal action in 2025 and 2026, and clone sites now trade on their names, so verify the company before the price. Curo lists MOTS-C 10mg for laboratory research with every lot's certificate published openly.

How much does MOTS-c cost?

Suppliers that publish lot-matched third-party COAs typically charge $60 to $100 for a 10mg research vial as of August 2026. Curo's 10mg vial is $69, or $6.90 per mg, with the lot's certificate published before purchase. Vials in the $35 to $45 band usually come without verifiable lot documentation.

What is the strongest evidence worth reading first?

Start with the mitochondrial-origin and folate-cycle/AMPK work, then the mouse metabolic and exercise protocols, and finally the K14Q cohort analysis. No verifiable human administration study exists yet.

What should a certificate of analysis for MOTS-c show?

Lot-specific identity and purity data from chromatographic and mass-spectrometry methods, checked against 2174.6 g/mol, plus endotoxin results, tied to the exact lot number on the vial and verifiable through a public lookup.